These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 20110517)
1. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE; J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517 [TBL] [Abstract][Full Text] [Related]
2. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Kyburz D; Gabay C; Michel BA; Finckh A; Rheumatology (Oxford); 2011 Jun; 50(6):1106-10. PubMed ID: 21258051 [TBL] [Abstract][Full Text] [Related]
3. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs? Ciubotariu E; Gabay C; Finckh A; J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383 [TBL] [Abstract][Full Text] [Related]
4. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? Jawaheer D; Maranian P; Park G; Lahiff M; Amjadi SS; Paulus HE J Rheumatol; 2010 Dec; 37(12):2475-85. PubMed ID: 20889597 [TBL] [Abstract][Full Text] [Related]
5. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). Lukas C; Combe B; Ravaud P; Sibilia J; Landew R; van der Heijde D Arthritis Rheum; 2011 Jul; 63(7):1804-11. PubMed ID: 21452295 [TBL] [Abstract][Full Text] [Related]
6. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519 [TBL] [Abstract][Full Text] [Related]
7. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K; Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE; Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846 [TBL] [Abstract][Full Text] [Related]
10. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185 [TBL] [Abstract][Full Text] [Related]
11. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs. Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M; J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390 [TBL] [Abstract][Full Text] [Related]
12. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638 [TBL] [Abstract][Full Text] [Related]
13. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969 [TBL] [Abstract][Full Text] [Related]
14. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645 [TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179 [TBL] [Abstract][Full Text] [Related]
16. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814 [TBL] [Abstract][Full Text] [Related]
17. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453 [TBL] [Abstract][Full Text] [Related]
18. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Mueller RB; Reshiti N; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; Schiff M; Spaeth M; von Kempis J; Clin Rheumatol; 2017 Jan; 36(1):59-66. PubMed ID: 27838788 [TBL] [Abstract][Full Text] [Related]
19. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. Combe B; Cantagrel A; Goupille P; Bozonnat MC; Sibilia J; Eliaou JF; Meyer O; Sany J; Dubois A; Daurès JP; Dougados M J Rheumatol; 2003 Nov; 30(11):2344-9. PubMed ID: 14677175 [TBL] [Abstract][Full Text] [Related]
20. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Krams T; Ruyssen-Witrand A; Nigon D; Degboe Y; Tobon G; Fautrel B; Berenbaum F; Cantagrel A; Constantin A Joint Bone Spine; 2016 Oct; 83(5):511-5. PubMed ID: 26992954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]